Skip to content

Comparsion of effects of Gonadotropin Releasing Hormon Agonists and Antagonists in ART cycles in infertile patients

Comparsion of effects of Gonadotropin Releasing Hormon Agonists and Antagonists in ART cycles in patients 35 years and older

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201109136626N3
Enrollment
120
Registered
2011-10-16
Start date
2011-09-11
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility. female infertility

Interventions

Intervention 1: Exogenic gonadotropin Gonal F 75unit IM daily and Monogon 150 unit IM daily both of them at 2th_3th of cycle if ovarians are inactive and endometial thickness is less than 4mm (in both
Treatment - Drugs
Exogenic gonadotropin Gonal F 75unit IM daily and Monogon 150 unit IM daily both of them at 2th_3th of cycle if ovarians are inactive and endometial thickness is less than 4mm (in both groups)
Gonadotropin Releasing Hormon Agonist (superfact) 0.5 cc subcutaneus daily from 21th day of cycle until diameter of dominant follicle reachs to 18_19mm (in group one)
Gonadotropin Releasing Hormon Antagonist (cetrotide) 3.5mg subcutaneus single dose (in second group)
Human chorionic gonadothropin (hcg)(pregnil)1000 unit IM single dose ,when diameter of dominant follicle reachs 18_19mm

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria:infertile women older than 35 years who are conditions for art and have not any endocreean desease or hypertantion or polycistic ovarian syndrom(pcos) or history of endometriosis or any surgery of ovarian Exclusion criteria: Infertile women smaller than 35 years old or have any endocreean desease or hypertantion or polycistic ovarian syndrom(pcos) or history of endometriosis or any surgery of ovarian

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Rate of documented pregnancy. Timepoint: Two mounths after the end of intervention. Method of measurement: Sonography.

Secondary

MeasureTime frame
Rate of abortion before 12 weeks of pregnancy. Timepoint: Four mounths after the end of intervention. Method of measurement: Sonography.;Severity of ovarian hyperstimulation syndrom. Timepoint: During one mounth after the end of intervention. Method of measurement: By examination and sonography.;Rate of chemical pregnancy. Timepoint: Two weeks after end of intervention. Method of measurement: unit/litter.;Prevalance of ovarian hyperstimulation syndrom. Timepoint: During one mounth after the end of intervention. Method of measurement: By examination and sonography.;Number of follicles which are growth. Timepoint: During of intervention(36 hours after hcg injection). Method of measurement: Sonography.;Number of the obtiened ovums. Timepoint: During the intervention(36 hours after hcg injection). Method of measurement: By counting.;Estradiol levels. Timepoint: During the intervention(day of hcg injection). Method of measurement: pg/ml.;Endometrial situation. Timepoint: During the intervention(day of hcg injection). Method of measurement: Sonography.;Duration of the stimulation for induction ovulation. Timepoint: During the intervention. Method of measurement: Days.;Number of the ampuls of gonadotropins used. Timepoint: During the intervention. Method of measurement: By counting.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeddighe Abdollahi

AL-zahra hospital,Tabriz university of medical science

dr-abdollahi@tbzmed.ac.ir+98 41 1553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026